MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer Net Income 2011-2026 | PKI
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 241 M | 270 M | 693 M | 943 M | 128 M | - | 228 M | 238 M | 234 M | 212 M | - | 158 M | 167 M | 7.7 M | 384 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 943 M | 7.7 M | 300 M |
Quarterly Net Income PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.7 M | 53.9 M | 42.2 M | - | 94.4 M | 55.4 M | 26 M | - | 9.5 M | 35.6 M | 569 M | - | 85.3 M | 179 M | 177 M | 380 M | 128 M | 246 M | 379 M | - | 177 M | 137 M | 33.7 M | 64.5 M | 58.6 M | 69.1 M | 35.4 M | 71.3 M | 76.5 M | 64.1 M | 26 M | -41.1 M | 91.1 M | 204 M | 38.6 M | 68.3 M | 58.1 M | 63.9 M | 47.5 M | - | 54.9 M | 49 M | 40.3 M | 30.8 M | 42.3 M | 50.5 M | 34.2 M | 66.9 M | 40.2 M | 27.9 M | 32.2 M | -15.9 M | 29.6 M | 33.6 M | 22.6 M | 293 M | 36.6 M | 29.8 M | 24.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 569 M | -41.1 M | 88.4 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
22.7 M | $ 8.96 | 1.01 % | $ 597 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-6.46 M | $ 13.67 | 0.15 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 25.94 | 0.43 % | $ 721 M | USA |
 |
DexCom
DXCM
|
836 M | $ 68.13 | 2.7 % | $ 26.6 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 154.1 | 1.4 % | $ 7.64 B | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 17.47 | 0.87 % | $ 931 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 88.35 | 1.34 % | $ 11.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-208 M | $ 103.93 | 0.08 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 15.57 | 4.11 % | $ 471 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
IQVIA Holdings
IQV
|
1.36 B | $ 168.8 | 2.43 % | $ 29 B | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 17.35 | 0.35 % | $ 2.25 B | USA |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 99.75 | 2.19 % | $ 8.23 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 2.86 | 0.7 % | $ 92.8 K | USA |
 |
Danaher Corporation
DHR
|
3.61 B | $ 195.49 | 2.14 % | $ 139 B | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.22 B | $ 122.2 | 2.45 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 199.41 | 0.23 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
83.6 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.21 B | $ 113.82 | 1.78 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
-112 M | $ 1.13 | 1.35 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
-59.4 M | $ 9.02 | 7.13 % | $ 256 M | Israel |
 |
NeoGenomics
NEO
|
-108 M | $ 8.31 | 0.85 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 9.26 | 1.59 % | $ 2.01 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 79.31 | 1.03 % | $ 5.35 B | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 1.42 | 4.04 % | $ 426 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-35.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 454.33 | 0.15 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 219.09 | 1.66 % | $ 25.1 B |  Schweiz |
 |
Celcuity
CELC
|
-112 M | $ 114.35 | -0.48 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 17.74 | 1.95 % | $ 397 M | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
-548 M | $ 200.3 | 1.33 % | $ 19.7 B | USA |
 |
OPKO Health
OPK
|
14 M | $ 1.2 | 0.42 % | $ 833 M | USA |